Photo Credit: Saicle
Breast Cancer is the Most Common Cancer in the United States, with more than 300,000 new cases estimated in 2025. In this article, Physician’s Weekly OFFERS A ROUNDUP OF CURRENT CLINICAL TRIALS INVESTIGATING TREATMENT REGIME FOR PATIES WITH BARREAS CANCER.
The Comet Study
Trial: Comparing an operation to monitoring, with or with -endocrine therapy trial for low risk dcis
Condition: Low-Trisk Ductal Carcinoma in Situ
Status: Active, not recruiting
Sponsor: Alliance Foundation Trials, LLC
Clinicaltrials.gov id: NCT02926911
Overview: Comet is a pragmatic, prospective, randomized trial designated to elucate the risks and benefits of active monitoring versus surgery among pavors with low-risk dcis.
The Study Notes That As Many As One In Four Patients with Breast Cancer Experience Overdiagnosis and Overtreatment, with dcis contributing signally to this burden. An Estimated 40,000 Paths with Dcis May Not Experience Disease Progression Without Treatment, and Overtreatment with Surgery Incurs Incursks Such as Chronic Pain, Disability, and Psychological Destress.
The Study Hypothesizes That Managing This Patient Population with Active Monitoring is Non-Infereior To Surgery in Terms of Cancer and Quality of Life Outcomes.
The Opt-Pumbroce Study
Trial: Personializing the use of pembrolizumab for patients who have the Strong Response in Early Triple Negative Breast cancer
Condition: Triple-Negative Breast Cancer
Status: Not Yet Recruiting
Sponsor: Unique
Clinicaltrials.gov id: NCT06606730
Overview: Opt-the-the-time is a pragmatic, prospective, randomized, phase 3 trial. The Researchers are Examining when Triple-Negative Breast Cancer Who has a Response to Neoadjuvant Treatment Have the Same Chance of Avoiding Recurence IF The Stop Pembrelizumab or Continue Receiving It for Another 6 Months.
Patients with Early, Triple-Negative Breast Cancer Usually Receive Chemotherapy and Immunotherapy for 6 Months Both Pre- and Post-surgery. The Current Study Speculates That post-surgery immunotherapy treatment may not offing any benefit to patients who have an excellent response to pre-surgical treatment, tumor disappearance, and a good prognosis.
The opt-the-the-part Study Will also Gather Date on Treatment Tolerance and Patients’ Quality of Life.
THE BRIA-ABC STUDY
Trial: Study of the Bria-Emit Regime and CPI vs Physicians’ Choice in Advanced Metastatic Breast Cancer Cancer
Condition: Advanced Metastatic or Locally Recurent Breast Cancer
Status: Recruiting
Sponsor: Briacell Therapeutics Corporation
Clinicaltrials.gov id: NCT06072612
Overview: BRIA-ABC IS A RANDOMIZED, OPEN-LABEL STUDY EXAMINING OVERALL SURVIVAL IN PATIES WITH Advanced Metastatic Or Locally Recurent Breast Cancer Who Receive Either a) The Bria-Est Regime Plus The Checkpoint Retifanlimab or b) Treatment of the Patientican’s Choice. The Researchers Will Also compare bria-in-the alone versus bria-it with the checkpoint inhibitor. Patients will be randomly Assigned 1: 1: 1 to Each Treatment Group.
The Bria-Emt Regime Includes The Immunotherapy Agent SV-BR-1-GM in Combination with Cyclophosphamide and Interferon.
The Cambria-2 Study
Trial: An adjuvant endochrine-based Therapy Study of CordesTrant (AZD9833) in Er+/Her2- Early Breast Cancer Cancer
Condition: Er+, Her2- Early Breast Cancer
Status: Recruiting
Sponsor: Astrazeneca
Clinicaltrials.gov id: NCT05952557
Overview: Cambria-2 is a Phase 3, Open-label Study Designed to compare invasive Breast Cancer-Free Survival with either trucks or Standard Adjuvant Endocrine Therapy in Patients with Er+, Her2- Early Breast Cancer. Patients Enrolling in This Study Must have intermediate-high or high risk and must have completed Locooregional Therapy with or Without Chemotherapy. The Study Notes That Patients in Both Arms Are Allowed to Receive Competant Abemacclib.
The Study Plans For Treatment Duration of 7 Years in Either Arm, as Well as 10 Years of Follow-Up from when the Last Patient is randomly assigned to treatment. Secondary Endpoints Include Invasive Disease-Free Survival, Distant Relapse-Free Survival, Overall Survival, and Safety and Clinical Outcome Assessments.
